Oragenics, Inc. (OGEN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Oragenics, Inc. (OGEN) is down 26.2% since the beginning of the year. At $1 per share, OGEN is trading 86.2% below its 52-week high of $4. Investors who bought $1,000 worth of OGEN shares 5 years ago would now be looking at an investment worth $0.

Oragenics, Inc. (OGEN) has returned -26.20% so far this year and -84.16% over the past 12 months. Over the last ten years, OGEN has returned -62.47% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Feb 25, 2004, OGEN's average daily return is +0.09%, while the average monthly return is -0.86%.

Historically, 38% of months were positive and 62% were negative. The best month was Sep 2018 with a return of +167.4%, while the worst month was Apr 2009 at -75.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, OGEN closed higher 37% of trading days. The best single day was Jun 30, 2009 with a return of +150.0%, while the worst single day was Jul 1, 2025 at -59.4%.

Oragenics, Inc. has an annualized alpha of 17.53%, beta of 0.55, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 25, 2004.

• This stock participated in 183.36% of S&P 500 Index downside but only -79.30% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.55 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

OGEN ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Oragenics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Oragenics, Inc. was 100.00%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Oragenics, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Oragenics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Oragenics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.